Skip to main content

Table 6 Stratification of the risks of death by HITAS score in patients with HBV–ACLF received glucocorticoid treatment

From: Early prediction model for prognosis of patients with hepatitis-B-virus-related acute-on-chronic liver failure received glucocorticoid therapy

Group

HITAS score

90-day mortality (%)

Training cohort %

Validation cohort %

Entire cohort %

Low-risk group

HITAS score ≤ 2.5

6.25

17.65

10.98

Intermediate-risk group

2.5 < HITAS score ≤ 3.47

32.56

57.14

36.00

High-risk group

HITAS score > 3.47

84.44

77.78

81.94